What's behind the counter?

Rezolve AI (NASDAQ: RZLV) is heading into its most consequential month since going public. Audited H1 2026 results land on the 1st of September, and court approval for the $300 million buyback and capital reduction is expected to follow within weeks. Together, these two events will do more to settle the debate around this stock than any amount of further commentary.

The buyback approval matters less for its size than for what it signals. A company with a track record of funding growth through repeated dilutive raises is now asking shareholders to approve capital return instead. Whether that reads as confidence or a play for sentiment will depend entirely on what the audit says a few weeks earlier.

The headline is whether $127 million in preliminary H1 revenue survives contact with an auditor. Management's own preliminary figures imply H1 revenue roughly 20x higher than the same period last year, and full-year guidance of $360 million would mean the second half alone needs to nearly match all of H1. That guidance leans heavily on a contracted revenue base said to exceed $230 million, meaning most of the year's growth is supposed to come from converting existing signed business rather than closing new deals. That's a different risk profile from a company growing on fresh bookings, and it's the number worth watching most closely once the audit lands.

It's also where the market's skepticism has the most grounding. CEO Dan Wagner has a history of overstating the scale of binding commitments in past ventures, and that history is precisely why "contracted" is doing so much work in this guidance. The market isn't just asking whether the pipeline is real, but whether "contracted" means what it's being presented to mean.

Beyond the H1 print itself, the bigger question is durability. Rezolve's own ARR targets imply a climb from roughly $90 million currently toward $500 million by the end of 2026, a trajectory that assumes enterprise sales cycles keep compressing and partner-driven demand keeps holding up. Any slowdown in enterprise AI adoption, or any lengthening of deal cycles, hits this target before it hits reported revenue, which is why ARR trajectory deserves at least as much attention as the H1 number itself.

None of this resolves in September. But it's the first real checkpoint: if the audited $127 million holds and the contracted base keeps converting on schedule, the market gets a reason to close some of the gap between share price and consensus targets. If it doesn't, the credibility questions that have followed this stock since IPO get considerably harder to wave away. Either way, the next few weeks tell you more about which story is right than anything written about Rezolve so far.